Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3–7 cm

 

 Permissions and Reprints

Abstract

Background of the Article: Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide. Radiofrequency ablation (RFA) is considered curative option in selected patients; efficacy is severely limited by lesion size and lesions bordering a large vessel. On the other hand, transarterial chemoembolization (TACE) is not limited by lesion size and arterial occlusion of the tumor feeding vessels leads to increase the volume of the ablative zone. Combination treatments using both intraarterial liver-directed therapy and percutaneous ablation seek to overcome the disadvantages of the individual treatments alone, theoretically improving response to therapy and survival. Material and Methods: This is a single-center retrospectively study in which patients who received TACE plus RFA for HCC were evaluated for technical success, local tumor progression rates, distant intra and extrahepatic recurrences and survival. Results: The study included 22 patients, 21 patients had a solitary HCC of size 3–7 cm and one patient had three target lesions. Technical success achieved after first session of combination treatment was 100% (24/24). At 1 and 3 months follow-up 100% patients (24 target lesions) had complete response and at 6 months; 21 (87.5%) had complete response, one (4.2%) had local tumor progression and two patients (8.3%) developed progressive disease. No major difference in complication was noted. The event-free survival as shown by Kaplan–Meier graph analysis at 6 and 12 months were 90.7% and 66.4% with mean time to event-free survival was 11.1 months. Conclusion: The combined use of TACE and RFA is a safe and effective option in the treatment of patients with single large or multinodular HCC when surgical resection is not feasible and this approach provides better results than RFA or TACE alone.

Publication History

Article published online:
23 July 2021

© 2019. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

• References

• 1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90
  CrossrefPubMedGoogle Scholar
• 2 Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2
  Google Scholar
• 3 N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E. et al. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50: 1475-83
  CrossrefPubMedGoogle Scholar
• 4 Iezzi R, Pompili M, Posa A, Coppola G, Gasbarrini A, Bonomo L. Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. World J Gastroenterol 2016; 22: 1935-42
  CrossrefPubMedGoogle Scholar
• 5 Takuma Y, Takabatake H, Morimoto Y, Toshikuni N, Kayahara T, Makino Y. et al. Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology 2013; 269: 927-37
  CrossrefPubMedGoogle Scholar
• 6 Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR. et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med 2016; 31: 242-52
  CrossrefPubMedGoogle Scholar
• 7 Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB. et al. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: Transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 2011; 18: 1624-9
  CrossrefPubMedGoogle Scholar
• 8 Yang D-j, Luo K-l, Liu H, Cai B, Tao G-q, Su X-f. et al. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget 2017; 8: 2960-70
  CrossrefPubMedGoogle Scholar
• 9 Liu H, Wang ZG, Fu SY, Li AJ, Pan ZY, Zhou WP. et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg 2016; 103: 348-56
  CrossrefPubMedGoogle Scholar
• 10 Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N. et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: Comparison with surgical resection. Cancer 2010; 116: 3638-44
  CrossrefPubMedGoogle Scholar
• 11 Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology 2009; 252: 905-13
  CrossrefPubMedGoogle Scholar
• 12 Carmi L, Georgiades C. Combination percutaneous and intraarterial therapy for the treatment of hepatocellular carcinoma: A review. Semin Intervent Radiol 2010; 27: 296-301
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Pan T, Mu LW, Wu C, Wu XQ, Xie QK, Li XS. et al. Comparison of Combined Transcatheter Arterial Chemoembolization and CT-guided Radiofrequency Ablation with Surgical Resection in Patients with Hepatocellular Carcinoma within the Up-to-seven Criteria: A Multicenter Case-matched Study. J Cancer 2017; 8: 3506-13
  CrossrefPubMedGoogle Scholar
• 14 Xie H, Wang H, An W, Ma W, Qi R, Yang B. et al. The efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma in a cohort of 487 patients. PLoS One 2014; 9: e89081
  CrossrefPubMedGoogle Scholar